88 related articles for article (PubMed ID: 15862138)
41. Expression, purification, and in vitro refolding of soluble tumor necrosis factor-related apoptosis-inducing ligand (TRAIL).
Lin Z; Lei H; Cao P
Protein Expr Purif; 2007 Feb; 51(2):276-82. PubMed ID: 17079165
[TBL] [Abstract][Full Text] [Related]
42. [Study of molecular mechanism of doxorubicin enhancement of TRAIL, inducing apoptosis of myeloma cell line KM3].
Wang HF; Chen ZH; Sun CY; Hu Y
Zhonghua Xue Ye Xue Za Zhi; 2007 Jan; 28(1):30-2. PubMed ID: 17649723
[TBL] [Abstract][Full Text] [Related]
43. Death receptor 5 promoter-enhancing compounds isolated from Catimbium speciosum and their enhancement effect on TRAIL-induced apoptosis.
Ohtsuki T; Kikuchi H; Koyano T; Kowithayakorn T; Sakai T; Ishibashi M
Bioorg Med Chem; 2009 Sep; 17(18):6748-54. PubMed ID: 19682913
[TBL] [Abstract][Full Text] [Related]
44. Quercetin sensitizes human hepatoma cells to TRAIL-induced apoptosis via Sp1-mediated DR5 up-regulation and proteasome-mediated c-FLIPS down-regulation.
Kim JY; Kim EH; Park SS; Lim JH; Kwon TK; Choi KS
J Cell Biochem; 2008 Dec; 105(6):1386-98. PubMed ID: 18980244
[TBL] [Abstract][Full Text] [Related]
45. Resistance of melanoma cells to TRAIL does not result from upregulation of antiapoptotic proteins by NF-kappaB but is related to downregulation of initiator caspases and DR4.
Kurbanov BM; Fecker LF; Geilen CC; Sterry W; Eberle J
Oncogene; 2007 May; 26(23):3364-77. PubMed ID: 17160022
[TBL] [Abstract][Full Text] [Related]
46. Prognostic significance of tumor necrosis factor-related apoptosis-inducing ligand and its receptors in adjuvantly treated stage III colon cancer patients.
van Geelen CM; Westra JL; de Vries EG; Boersma-van Ek W; Zwart N; Hollema H; Boezen HM; Mulder NH; Plukker JT; de Jong S; Kleibeuker JH; Koornstra JJ
J Clin Oncol; 2006 Nov; 24(31):4998-5004. PubMed ID: 17075118
[TBL] [Abstract][Full Text] [Related]
47. Apoptosis-related factors (TRAIL, DR4, DR5, DcR1, DcR2, apoptotic cells) and proliferative activity in ameloblastomas.
Rizzardi C; Leocata P; Ventura L; Zweyer M; Brollo A; Schneider M; Melato M
Anticancer Res; 2009 Apr; 29(4):1137-42. PubMed ID: 19414356
[TBL] [Abstract][Full Text] [Related]
48. A placental protective role for trophoblast-derived TNF-related apoptosis-inducing ligand (TRAIL).
Bai X; Williams JL; Greenwood SL; Baker PN; Aplin JD; Crocker IP
Placenta; 2009 Oct; 30(10):855-60. PubMed ID: 19674787
[TBL] [Abstract][Full Text] [Related]
49. Characterisation of TNF-related apoptosis-inducing ligand in peripheral blood in patients with primary biliary cirrhosis.
Liang Y; Yang Z; Li C; Zhu Y; Zhang L; Zhong R
Clin Exp Med; 2008 Mar; 8(1):1-7. PubMed ID: 18385934
[TBL] [Abstract][Full Text] [Related]
50. Impact of soluble tumor necrosis factor-related apoptosis-inducing ligand released by engineered adipose mesenchymal stromal cells on white blood cells.
Casari G; Dall'Ora M; Melandri A; Masciale V; Chiavelli C; Prapa M; Neri G; Spano MC; Murgia A; D'Esposito A; Baschieri MC; Ceccherelli GB; Dominici M; Grisendi G
Cytotherapy; 2023 Jun; 25(6):605-614. PubMed ID: 37012089
[TBL] [Abstract][Full Text] [Related]
51. Construction and expression of sTRAIL-melittin combining enhanced anticancer activity with antibacterial activity in Escherichia coli.
Liu H; Han Y; Fu H; Liu M; Wu J; Chen X; Zhang S; Chen Y
Appl Microbiol Biotechnol; 2013 Apr; 97(7):2877-84. PubMed ID: 23149754
[TBL] [Abstract][Full Text] [Related]
52. The release of soluble forms of TRAIL and DR5 by neutrophils of oral cavity cancer patients.
Jablonska E; Jablonski J; Marcinczyk M; Grabowska Z; Piotrowski L
Folia Histochem Cytobiol; 2008; 46(2):177-83. PubMed ID: 18519235
[TBL] [Abstract][Full Text] [Related]
53. Induction of apoptosis by recombinant soluble human TRAIL in Jurkat cells.
Yao GH; Ling LJ; Luan JF; Ye D; Zhu PY; Lei QH
Biomed Environ Sci; 2007 Dec; 20(6):470-7. PubMed ID: 18348405
[TBL] [Abstract][Full Text] [Related]
54. Serum-soluble TRAIL: a potential biomarker for disease activity in myositis patients.
Zhou H; Wang Y; Bi K; Qi H; Song S; Zhou M; Chen L; Wang G; Duan T
Clin Rheumatol; 2019 May; 38(5):1425-1431. PubMed ID: 30645753
[TBL] [Abstract][Full Text] [Related]
55. Aureobasidium pullulans culture supernatant significantly stimulates R-848-activated phagocytosis of PMA-induced THP-1 macrophages.
Tamegai H; Takada Y; Okabe M; Asada Y; Kusano K; Katagiri YU; Nagahara Y
Immunopharmacol Immunotoxicol; 2013 Aug; 35(4):455-61. PubMed ID: 23786444
[TBL] [Abstract][Full Text] [Related]
56. Nature and dynamics of nucleosome release from neoplastic and non-neoplastic cells.
Holdenrieder S; Kolligs FT; Braess J; Manukyan D; Stieber P
Anticancer Res; 2012 May; 32(5):2179-83. PubMed ID: 22593507
[TBL] [Abstract][Full Text] [Related]
57. Expression, purification and characterization of heterotrimeric forms of sTRAIL using a polycistronic expression vector.
Wang B; Wang Z; Yan J; Wang L; Wang Z; Wu J; Zhang H; Wu H; Kong W; Yu B; Yu X
Protein Expr Purif; 2015 Nov; 115():118-24. PubMed ID: 26256060
[TBL] [Abstract][Full Text] [Related]
58. Targeted induction of apoptosis in glioblastoma multiforme cells by an MRP3-specific TRAIL fusion protein in vitro.
Wang LH; Ni CW; Lin YZ; Yin L; Jiang CB; Lv CT; Le Y; Lang Y; Zhao CY; Yang K; Jiao BH; Yin J
Tumour Biol; 2014 Feb; 35(2):1157-68. PubMed ID: 24272336
[TBL] [Abstract][Full Text] [Related]
59. Regulation of galectin-9 expression and release in Jurkat T cell line cells.
Chabot S; Kashio Y; Seki M; Shirato Y; Nakamura K; Nishi N; Nakamura T; Matsumoto R; Hirashima M
Glycobiology; 2002 Feb; 12(2):111-8. PubMed ID: 11886844
[TBL] [Abstract][Full Text] [Related]
60. Development, characterization and use of monoclonal antibodies against sTRAIL: measurement of sTRAIL by ELISA.
Liabakk NB; Sundan A; Torp S; Aukrust P; Frøland SS; Espevik T
J Immunol Methods; 2002 Jan; 259(1-2):119-28. PubMed ID: 11730847
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
